Evercore Lowers Azenta Price Target to $35 but Maintains Outperform Rating
On April 6, Evercore ISI reduced its price target for Azenta (NASDAQ:AZTA) from $45 to $35 while keeping an 'Outperform' rating. The adjustment was part of the firm's Q1 outlook on medical technology and life science tools sectors.
Topics: Analyst Rating Leadership Change Medical Technology Multiomics